Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Ironwood Pharmaceuticals (NASDAQ:IRWD) has received an average rating of "Hold" from seven brokerages, with six holding and one buying the stock, and a 1-year price target of $4.94.
• The company recently posted quarterly earnings of $0.14 per share, outperforming analysts' expectations and generating revenue of $85.24 million, well above the forecasted $62.02 million.
• Institutional investors have shown significant interest, with several hedge funds greatly increasing their stakes in Ironwood Pharmaceuticals during the first quarter, including Acadian Asset Management, which raised its holdings by 160.7%.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have received an average rating of "Hold" from the seven brokerages that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $4.94.

A number of research analysts recently weighed in on IRWD shares. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Zacks Research cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 5th.

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $1.61 on Friday. The stock has a 50-day simple moving average of $1.15 and a two-hundred day simple moving average of $0.96. The firm has a market capitalization of $261.51 million, a PE ratio of -32.19 and a beta of 0.30. Ironwood Pharmaceuticals has a 52-week low of $0.53 and a 52-week high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. The firm had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 160.7% in the first quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company's stock worth $3,878,000 after buying an additional 1,630,726 shares in the last quarter. Voleon Capital Management LP increased its holdings in Ironwood Pharmaceuticals by 952.4% in the 1st quarter. Voleon Capital Management LP now owns 870,629 shares of the biotechnology company's stock valued at $1,280,000 after acquiring an additional 787,901 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Ironwood Pharmaceuticals by 3,683.6% in the 1st quarter. GSA Capital Partners LLP now owns 524,676 shares of the biotechnology company's stock worth $771,000 after purchasing an additional 510,809 shares in the last quarter. Inspire Investing LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 159.7% during the 1st quarter. Inspire Investing LLC now owns 231,825 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 142,574 shares during the last quarter. Finally, Pallas Capital Advisors LLC grew its position in shares of Ironwood Pharmaceuticals by 454.5% during the second quarter. Pallas Capital Advisors LLC now owns 79,512 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 65,172 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.